<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01123317</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00041288</org_study_id>
    <nct_id>NCT01123317</nct_id>
  </id_info>
  <brief_title>Brain Blood Flow Changes Elicited by Oxytocin in Volunteers With and Without Schizophrenia</brief_title>
  <official_title>Brain Blood Flow Changes Elicited by Oxytocin in Healthy and Schizophrenic Volunteers, an Assessment Using Positron Emission Tomography and 15-Oxygen Labeled Water</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess how oxytocin delivered intranasally changes regional&#xD;
      brain blood flow measured by positron emission tomography (PET) in conjunction with oxygen-15&#xD;
      labeled water in persons with schizophrenia. The objective is to better our understanding of&#xD;
      oxytocin's role in the modulation of social judgment in schizophrenia and provide more&#xD;
      information as to potential uses of oxytocin or a similar drug analog in treating certain&#xD;
      features of schizophrenia and other neuropsychiatric disorders.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Schizophrenia is a severely debilitating psychiatric disorder that afflicts approximately 1%&#xD;
      of the population (American Psychiatric Association, 1994) and is a serious public health&#xD;
      problem. The specific mechanism of schizophrenia remains unknown. Affective responsivity and&#xD;
      adaptive social behaviors are fundamental impairments in people with schizophrenia. These&#xD;
      features have a detrimental impact on function in many areas of daily life. Unfortunately,&#xD;
      the brain mechanisms that underlie these problems are still not understood. This study will&#xD;
      use positron emission tomography (PET) and regional cerebral blood flow (rCBF) measures to&#xD;
      ascertain the timing (1.5 hour period) of OT action on absolute regional brain activity in&#xD;
      schizophrenia (SZ) and healthy control (HC) subjects. Particular focus will be on the&#xD;
      amygdala, ventral striatum, anterior hippocampus and hypothalamus (neural regions involved in&#xD;
      affliative behavior). Subjects will be studied with intranasally administered oxytocin and&#xD;
      placebo while at rest and while making judgments about emotional faces. This approach will&#xD;
      tell us to what extent the amygdala and limbic system's physiological response to oxytocin is&#xD;
      predictive of a subject's behavioral sensitivity to this neuropeptide. The elucidation of&#xD;
      this information may have a significant impact on predicting functional outcome and novel&#xD;
      drug treatments in schizophrenia.&#xD;
&#xD;
      Functional magnetic resonance imaging (MRI) studies show that oxytocin modulates the&#xD;
      amygdala's response during social and emotional decisions. When administered intranasally, OT&#xD;
      may be beneficial for the treatment of negative symptoms in schizophrenia by enhancing a&#xD;
      person's affiliative behavior and diminishing distrust. It is not, however, known to what&#xD;
      extent intranasal oxytocin modifies regional neurotransmission and human brain metabolism.&#xD;
      There are at present no studies in animals or humans specifically examining the time course&#xD;
      action of OT on whole brain activity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Never started&#xD;
  </why_stopped>
  <start_date>July 2010</start_date>
  <completion_date type="Anticipated">January 2013</completion_date>
  <primary_completion_date type="Anticipated">January 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oxytocin induced rCBF changes</measure>
    <time_frame>2 years</time_frame>
    <description>Oxytocin induced rCBF changes in the amygdala, ventral striatum, hypothalamus and anterior hippocampus (post-drug versus pre-drug, resting and task conditions</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Oxytocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomly assigned to either OT-Placebo or Placebo-OT order for PET scan drug administration and will receive the first of the two intranasal doses at Pet scan 1 and the second intranasal dose of the subsequent treatment at Pet Scan 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>Subjects will be randomly assigned to either OT-Placebo or Placebo-OT order for PET scan drug administration and will receive the first of the two intranasal doses at Pet scan 1 and the second intranasal dose of the subsequent treatment at Pet Scan 2</description>
    <arm_group_label>Oxytocin</arm_group_label>
    <other_name>Syntocinon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Normal volunteers: Age range: 18-55 years of age&#xD;
&#xD;
          -  Normal Volunteers: No psychiatric illness in self; no psychotic illness in first&#xD;
             degree relatives&#xD;
&#xD;
          -  Normal Volunteers: No previous history of substance dependence in last 6 months; no&#xD;
             substance abuse in last month&#xD;
&#xD;
          -  Normal Volunteers: No contraindication for MRI scanning (i.e. cardiac pacemaker,&#xD;
             prosthesis)&#xD;
&#xD;
          -  Normal Volunteers: Not pregnant&#xD;
&#xD;
          -  Normal Volunteers: No major medical illness (e.g. seizure disorder) or medication that&#xD;
             affects brain structure (e.g. steroids)&#xD;
&#xD;
          -  Normal Volunteers: Participation in Healthy Subject Recruitment protocol&#xD;
             (HP-00042350).&#xD;
&#xD;
          -  Patient Volunteers: DSM-IV diagnosis of schizophrenia&#xD;
&#xD;
          -  Patient Volunteers: Voluntary and competent to sign an informed consent&#xD;
&#xD;
          -  Patient Volunteers: No contraindication for MRI scanning (i.e. cardiac pacemaker,&#xD;
             prosthesis)&#xD;
&#xD;
          -  Patient Volunteers: No previous history of substance dependence in last 6 months; no&#xD;
             substance abuse in last month&#xD;
&#xD;
          -  Patient Volunteers: Not pregnant&#xD;
&#xD;
          -  Patient Volunteers: No major medical illness other than schizophrenia that affects&#xD;
             brain structure (e.g. seizure disorder); not currently taking medication other than&#xD;
             that for schizophrenia that affects brain structure (e.g. steroids)&#xD;
&#xD;
          -  Patient Volunteers: No diagnosis of Major Depressive Disorder within last 6 months&#xD;
&#xD;
          -  Patient Volunteers: SANS Asociality global score 2 or greater&#xD;
&#xD;
          -  Patient Volunteers: No change in antipsychotic medication (type and dose) within the&#xD;
             last 4 weeks&#xD;
&#xD;
          -  Patient volunteers: Age range: 18-55 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Normal Volunteers: Age outside of specified range -Normal Volunteers: Psychiatric&#xD;
             illness in self; psychotic illness in first- degree relative&#xD;
&#xD;
          -  Normal Volunteers: Previous history of substance dependence in last 6 months;&#xD;
             substance abuse in last month&#xD;
&#xD;
          -  Normal Volunteers: Contraindication for MRI scanning (i.e. cardiac pacemaker,&#xD;
             prosthesis)&#xD;
&#xD;
          -  Normal Volunteers: Pregnant&#xD;
&#xD;
          -  Normal Volunteers: Major medical illness (e.g. seizure disorder) or medication that&#xD;
             affects brain structure (e.g. steroids)&#xD;
&#xD;
          -  Patient Volunteers: Age outside of specified range&#xD;
&#xD;
          -  Patient Volunteers: Contraindication for MRI scanning (i.e. cardiac pacemaker,&#xD;
             prosthesis)&#xD;
&#xD;
          -  Patient Volunteers: History of substance dependence in last 6 months; substance abuse&#xD;
             in last month&#xD;
&#xD;
          -  Patient Volunteers: Pregnancy&#xD;
&#xD;
          -  Patient Volunteers: Major medical illness other than schizophrenia that affects brain&#xD;
             structure; currently taking medication other than that for schizophrenia that affects&#xD;
             brain structure&#xD;
&#xD;
          -  Patient Volunteers: Diagnosis of Major Depressive Disorder within last 6 months&#xD;
&#xD;
          -  Patient Volunteers: SANS Asociality global score &lt; 2&#xD;
&#xD;
          -  Patient Volunteers: Change in antipsychotic medication (type and dose) within the last&#xD;
             4 weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henry Holcomb, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>MPRC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maryland Psychiatric Research Center</name>
      <address>
        <city>Catonsville</city>
        <state>Maryland</state>
        <zip>21228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>May 12, 2010</study_first_submitted>
  <study_first_submitted_qc>May 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2010</study_first_posted>
  <last_update_submitted>August 15, 2019</last_update_submitted>
  <last_update_submitted_qc>August 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, Baltimore</investigator_affiliation>
    <investigator_full_name>Robert Buchanan</investigator_full_name>
    <investigator_title>Director, Maryland Psychiatric Research Center</investigator_title>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>PET</keyword>
  <keyword>Oxytocin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

